Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Injectable Insulin · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Human Insulin Inhalation Powder | DRUG | patient specific dose, inhaled, before meals, 6 months |
| Injectable insulin | DRUG | patient specific dose, injected, before meals, 6 months |
| Insulin Glargine | DRUG | patient specific dose, injectable, before meals, 6 months |
Inclusion Criteria: * Type 1 diabetes for at least 24 months * Have an HbA1c less than or equal to 11% * Patients who are on an insulin regimen involving 2 or 3 preprandial injections per day for at least 2 months * Non-smoker Exclusion Criteria: * Require a daily total insulin dosage greater tha...
Injectable Insulin is used for the treatment of Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2. It is a small molecule metabolic therapy being developed by Eli Lilly and Company. The drug is currently in Phase 3 clinical development for these indications.
Injectable Insulin is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's efficacy in patients with Type 1 and Type 2 diabetes.
Injectable Insulin is in Phase 3 clinical development. Eli Lilly and Company has completed three Phase 3 trials for the drug, studying its use in patients with Type 1 and Type 2 diabetes. The drug remains investigational and is not yet approved for commercial use.
Injectable Insulin has completed three Phase 3 clinical trials: NCT00127634 in Type 1 diabetes with 385 patients, NCT00325364 in Type 2 diabetes with 415 patients, and NCT00356109 in Type 1 diabetes with 494 patients. All trials were completed and enrolled adult patients.
Injectable Insulin is related to human insulin inhalation powder, as two of its Phase 3 trials studied this formulation. However, the drug name Injectable Insulin refers to the general insulin product being developed by Eli Lilly, and the inhalation powder represents a specific delivery form tested in clinical trials.